Digital Analysis of Plasma miRNA populations in Pancreatic Cancer

 描述（由申请人提供）：对稳健、可靠和微创诊断技术的需求代表了对早期检测、分层 以及对侵袭性癌症的监控。无细胞microRNA（miRNAs）代表了一类新的生物标志物，在最初的研究中显示出希望，并可能具有重要的临床实用性。然而，有效和准确地鉴定和定量循环miRNA群体的能力是具有挑战性的，并且目前的方法不能满足在筛选和监测应用中广泛采用所必需的高特异性、灵敏度、可及性和再现性的要求。在第一阶段SBIR应用中，RedVault Biosciences提出建立一种新型多重诊断平台的可行性，以表征循环细胞 游离的miRNA群体，特别是那些在胰腺癌诊断、分层和干预中直接有用的miRNA。这项广泛支持的技术利用先进分子基因组学、合成生物学和数字核酸分析的新进展，显著减少当前复杂的实验室工作流程，并提供定量、可重复和临床信息的结果。这项技术的成功开发可以提供基本信息，对miRNA研究、疾病管理和患者生存产生积极影响。

 DESCRIPTION (provided by applicant): The demand for robust, reliable, and minimally invasive diagnostic technologies represents a pressing need in the early detection, stratification, and surveillance of aggressive cancers. Cell-free microRNAs (miRNAs) represent a novel class of biomarkers that have shown promise during initial studies and may have significant clinical utility. The ability to efficiently and accurately identify and quantify circulating miRNA populatins is challenging however, and current approaches fail to meet the requirements of high specificity, sensitivity, accessibility, and reproducibility necessary for widespread adoption in screening and monitoring applications. In this phase I SBIR application, RedVault Biosciences proposes to establish the feasibility of a novel multiplex diagnostic platform to characterize circulating cell free miRNA populations, specifically those miRNAs of immediate utility in pancreatic cancer diagnosis, stratification, and intervention. The broadly-enabling technology leverages novel advancements in advanced molecular genomics, synthetic biology, and digital nucleic acid analysis to significantly reduce current, complex laboratory workflows and provide quantitative, reproducible and clinically informative results. Successful development of this technology could provide fundamental information to positively affect miRNA research, disease management, and patient survival.